Department of Ophthalmology, Dean A. McGee Eye Institute, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma 73104, USA.
J Ocul Pharmacol Ther. 2012 Dec;28(6):647-9. doi: 10.1089/jop.2011.0244. Epub 2012 Aug 17.
Report the use of bevacizumab intralesional injection as an adjunctive therapy in a patient with ocular surface squamous neoplasia (OSSN) after an incomplete response to topical and intralesional chemotherapy.
This is a case report of a 79-year-old man who was treated with topical and intralesional chemotherapy (interferon-alpha-2b, mitomycin-C, and 5-fluorouracil) over 22 months with incomplete resolution of severe OSSN. Intralesional bevacizumab was tried as an adjuvant treatment to resolve the residual tumor.
Grossly and histologically there was no significant change in the residual tumor after treatment with intralesional bevacizumab.
While intralesional bevacizumab has been utilized as a treatment modality in the use of other squamous tumors, further studies on the use of bevacizumab in squamous neoplasia would be needed to recommend this treatment for the ocular surface. In the absence of further studies, the current topical and intralesional chemotherapeutic agents should continue to be the mainstay of medical treatment for squamous neoplasia; surgical management is still the definitive treatment.
报告贝伐单抗病灶内注射作为眼表面鳞状细胞肿瘤（OSSN）患者局部和病灶内化疗不完全反应后的辅助治疗的应用。
这是一名 79 岁男性的病例报告，他接受了 22 个月的局部和病灶内化疗（干扰素-α-2b、丝裂霉素 C 和 5-氟尿嘧啶）治疗，但严重 OSSN 不完全缓解。尝试病灶内贝伐单抗作为辅助治疗以解决残留肿瘤。
病灶内贝伐单抗治疗后，残留肿瘤的大体和组织学均无明显变化。
虽然病灶内贝伐单抗已被用于其他鳞状肿瘤的治疗方式，但需要进一步研究贝伐单抗在鳞状肿瘤中的应用，以推荐该治疗方法用于眼表面。在缺乏进一步研究的情况下，目前的局部和病灶内化疗药物仍应继续作为鳞状肿瘤的主要治疗方法；手术治疗仍然是明确的治疗方法。
